Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Abeona Therapeutics (ABEO) over the last 7 years, with Q4 2017 value amounting to $3.1 million.

  • Abeona Therapeutics' Non-Current Deffered Revenue fell 1645.74% to $3.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $3.1 million, marking a year-over-year decrease of 1645.74%. This contributed to the annual value of $3.1 million for FY2017, which is 1645.74% down from last year.
  • As of Q4 2017, Abeona Therapeutics' Non-Current Deffered Revenue stood at $3.1 million, which was down 1645.74% from $3.2 million recorded in Q3 2017.
  • In the past 5 years, Abeona Therapeutics' Non-Current Deffered Revenue registered a high of $5.5 million during Q2 2013, and its lowest value of $2.6 million during Q1 2013.
  • Over the past 5 years, Abeona Therapeutics' median Non-Current Deffered Revenue value was $4.3 million (recorded in 2015), while the average stood at $4.3 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Non-Current Deffered Revenue skyrocketed by 10121.03% in 2014, and later crashed by 1645.74% in 2017.
  • Abeona Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $5.2 million in 2013, then dropped by 7.12% to $4.9 million in 2014, then decreased by 12.37% to $4.3 million in 2015, then fell by 14.11% to $3.7 million in 2016, then fell by 16.46% to $3.1 million in 2017.
  • Its last three reported values are $3.1 million in Q4 2017, $3.2 million for Q3 2017, and $3.4 million during Q2 2017.